154 related articles for article (PubMed ID: 33754223)
1. Comment on "Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature".
Maatallah K; Ben Nessib D; Hamdi W
Clin Rheumatol; 2021 May; 40(5):2109-2110. PubMed ID: 33754223
[No Abstract] [Full Text] [Related]
2. Rebuttal letter on "Comment on Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature".
Rocha FAC; Deodhar A
Clin Rheumatol; 2021 May; 40(5):2107-2108. PubMed ID: 33754222
[No Abstract] [Full Text] [Related]
3. Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature.
Rocha FAC; Pinto ACMD; Lopes JR; Deodhar A
Clin Rheumatol; 2021 May; 40(5):1881-1887. PubMed ID: 33230684
[TBL] [Abstract][Full Text] [Related]
4. Etanercept for Ankylosing Spondylitis With Coexisting Demyelinating Myelitis.
Ye C; Geng Z; Li S; Yu F
Am J Ther; 2019; 26(5):e629-e631. PubMed ID: 30199382
[No Abstract] [Full Text] [Related]
5. Polychondritis in a Patient With Ankylosing Spondylitis on an Anti-TNF-α Biosimilar Agent.
Duro T; Li S; Jose D; Khawar T
J Clin Rheumatol; 2021 Dec; 27(8S):S656. PubMed ID: 35073638
[No Abstract] [Full Text] [Related]
6. Muscular sarcoidosis under anti-TNF treatment in ankylosing spondylitis.
Wendling D; Nueffer JP
Joint Bone Spine; 2018 Dec; 85(6):769. PubMed ID: 29787812
[No Abstract] [Full Text] [Related]
7. Maintenance of Low Disease Activity following Tumor Necrosis Factor Inhibitor Dose Tapering in Ankylosing Spondylitis.
Steel L; Gaffney K
J Rheumatol; 2017 Aug; 44(8):1292. PubMed ID: 28765347
[No Abstract] [Full Text] [Related]
8. Effect of etanercept on iritis in patients with ankylosing spondylitis.
Rosenbaum JT
Arthritis Rheum; 2004 Nov; 50(11):3736-7. PubMed ID: 15529379
[No Abstract] [Full Text] [Related]
9. A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept.
Zeremski V; Savić A; Ilić T; Milosević I; Maksimović M; Vucković B
Srp Arh Celok Lek; 2016; 144(1-2):81-4. PubMed ID: 27276864
[TBL] [Abstract][Full Text] [Related]
10. Radiographic Evidence of Hip Joint Recovery in Patients with Ankylosing Spondylitis after Treatment with Anti-tumor Necrosis Factor Agents: A Case Series.
Song R; Chung SW; Lee SH
J Rheumatol; 2017 Nov; 44(11):1759-1760. PubMed ID: 29093078
[No Abstract] [Full Text] [Related]
11. Scrotal pain of a patient with ankylosing spondylitis successfully treated with TNF-alpha inhibitor: a case report.
Suzuki H; Tsujimoto T; Ota M; Hasegawa Y; Oha F; Shimamura Y; Tanaka M; Hashimoto T; Iwasaki N; Kanayama M
J Orthop Sci; 2024 Jan; 29(1):402-404. PubMed ID: 35690543
[No Abstract] [Full Text] [Related]
12. Palmoplantar pustulosis secondary to anti-tumor necrosis factor therapy in a patient with ankylosing spondylitis.
Bae JM; Eun SH; Kim KJ
Korean J Intern Med; 2020 Jan; 35(1):254-255. PubMed ID: 31623028
[No Abstract] [Full Text] [Related]
13. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
[TBL] [Abstract][Full Text] [Related]
14. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
[No Abstract] [Full Text] [Related]
15. Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study.
van der Weijden MA; van Denderen JC; Lems WF; Nurmohamed MT; Dijkmans BA; van der Horst-Bruinsma IE
J Rheumatol; 2016 Apr; 43(4):758-64. PubMed ID: 26879348
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
17. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
Gorman JD; Sack KE; Davis JC
N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
[TBL] [Abstract][Full Text] [Related]
18. Correlations of CYP2C9*3/CYP2D6*10/CYP3A5*3 gene polymorphisms with efficacy of etanercept treatment for patients with ankylosing spondylitis: A case-control study.
Chen YY
Medicine (Baltimore); 2017 Mar; 96(9):e5993. PubMed ID: 28248857
[TBL] [Abstract][Full Text] [Related]
19. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
[TBL] [Abstract][Full Text] [Related]
20. Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.
Ibáñez Vodnizza SE; Nurmohamed MT; Visman IM; van Denderen JC; Lems WF; Jaime F; van der Horst-Bruinsma IE
J Rheumatol; 2017 Sep; 44(9):1355-1361. PubMed ID: 28711878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
